

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

April 22, 2015

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for February 4, 2015 meeting (pages 3-8; Tab1)
- IV. Secretary's report (page 9; Tab 2)
- V. Old Business (Tab 3)
 - A. Proposed protocol for the safe and efficient use of opioids in acute pain (page 11)
 - B. HMO (UHC) response to DURB follow-up questions regarding protocols (page 12)
- VI. New Business
 - A. Sofosbuvir/ledipasvir (Harvoni[®]) proposed protocol (pages 13-16; Tab 4)
 - B. Ombitasvir, paritaprevir, ritonavir and dasabuvir (Viekira[®]) proposed protocol (pages 17-28; Tab 5)
 - C. Protocols review (pages 29-44; Tab 6)
 - 1. Erythropoietin Stimulating Agents (ESA)
 - 2. Repository corticotropin (H.P. Acthar Gel[®])
- VII. Informational Highlights/Reports
 - 1. Molina/NJ HMO 4th Quarter 2014 Prior Authorization Report (pages 45-46; Tab 7)
 - 2. Summary of DURB Action Items (pages 47-48; Tab 8)
 - 3. DHS and DHSS Programs Top Drugs Report (pages 49-60; Tab 9)
 - 4. Medication information: (pages 61-64; Tab 10)
 - (a) FDA approves Evotaz[®] for HIV treatment
 - (b) FDA approves Prezcofix[®] for HIV treatment
 - (c) Antipsychotic overuse not just a problem in nursing homes
 - (d) FDA: Testosterone Labels Must Now Note CV, Stroke Risks